



Lori A. Shibinette  
Commissioner

Henry D. Lipman  
Director

STATE OF NEW HAMPSHIRE  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF MEDICAID SERVICES

129 PLEASANT STREET, CONCORD, NH 03301  
603-271-9422 1-800-852-3345 Ext. 9422  
Fax: 603-271-8431 TDD Access: 1-800-735-2964  
[www.dhhs.nh.gov](http://www.dhhs.nh.gov)

Guidance for Providers on the Medicaid COVID-19 Group (formerly known as COVID-19 Testing Group) February 2, 2022 (Updates December 30, 2021 Guidance)

**Medicaid COVID-19 Group**

The Medicaid COVID-19 Testing Group is now known as the Medicaid COVID-19 Group, as vaccine administration and certain treatments for COVID-19 are now also covered under this eligibility group. This is an update to the Guidance for Providers issued October 29, 2020. This update provides information about the expanded covered services. **New information is in red.**

New Hampshire Medicaid opted to cover testing and diagnostic related services for uninsured residents of New Hampshire through the Medicaid program in June 2020 under the authority provided by the Families First Coronavirus Response Act (FFCRA). To receive coverage, an uninsured patient is required to apply using the streamlined Medicaid application and qualify. (Further information regarding how to apply for this coverage is noted below.) Coverage was expanded to include COVID 19 vaccine administration and certain treatment under the American Rescue Plan Act of 2021 (ARPA). The expanded coverage includes hospitalizations, emergency room visits, urgent care clinic visits, telemedicine visits, and office visits for the treatment of COVID-19.

Below is information for clinical providers about the eligibility and services provided for this new Medicaid Eligibility Group. Please note that further guidance from CMS is still forthcoming and this information will be updated as it becomes available.

**Who is eligible for the Medicaid COVID-19 Group?**

Individuals who either do not have insurance or are enrolled in a limited benefit Medicaid eligibility group (i.e. individuals eligible for family planning and related services or individuals eligible as “medically needy with spenddown”) may be eligible for coverage. Individuals enrolled in short-term, limited-duration health insurance plans<sup>1</sup> that do not cover COVID-19 testing, vaccine administration and/or treatment are also considered eligible for this Medicaid COVID-19 Group. In addition, individuals participating in Healthcare Sharing Plans may also be eligible for this group since Healthcare Sharing plans are not health insurance. There is no income limit or resource test for this group. In addition to being uninsured, in a limited benefit Medicaid eligibility group, or in a short-term health insurance plan, an individual must be a NH resident, a US citizen or have qualifying immigration status and provide a social security number (SSN).

---

<sup>1</sup> CMS defines short-term, limited-duration insurance as “a type of health insurance coverage that was primarily designed to fill gaps in coverage that may occur when an individual is transitioning from one plan or coverage to another plan or coverage, such as in between jobs

## **Are individuals who have health insurance, but need a COVID-19 test for public health surveillance or other reasons that is not for the specific benefit of the patient, eligible for testing coverage under this Medicaid COVID-19 Group?**

Our understanding at this time is that Medicaid will only cover COVID-19 tests and diagnostic related services, vaccine administration and treatment that are medically necessary as determined by the health care provider. Please refer to the NH DHHS Health Alerts (HAN) [#19: COVID-19 Outbreak Update](#) and [#23: Antigen Testing Updated Recommendations](#) regarding recommendations for testing, which includes persons with even mild symptoms of COVID-19 and asymptomatic patients. More information on testing can be found on the [COVID-19 Healthcare Provider](#) page.

Health care providers determine if a pre-symptomatic or asymptomatic person should be tested for COVID-19 as a medically necessary service in the setting of potential community exposure, travel or mass transit exposure, or exposure to a close contact of people with suspected or confirmed COVID-19.

There are ICD-10 diagnosis codes that indicate medical necessity for the symptomatic and asymptomatic testing. Providers should use the ICD-10 codes for any of the symptoms of COVID-19 as the ordering code for the test, and if testing someone who is asymptomatic use the ICD-10 code Z20.828- Contact with and (suspected) exposure to other viral communicable diseases, which indicates that the person may have potential exposure to the virus and thus it is medically necessary to test. The current CDC coding rules for testing for COVID-19 can be found here: [CDC ICD-10-CM Official Guidelines for Coding and Reporting](#).

This applies to Medicaid in general as well as the Medicaid COVID-19 Group. We will inform providers and stakeholders if CMS provides further guidance.

## **What services are now covered under the Medicaid COVID-19 Group?**

Covered testing services include telehealth or in-person visits for diagnostic evaluation of COVID-19, chest x-rays for the purpose of diagnosing COVID-19, specimen collection and testing for COVID-19 with PCR or antigen-based testing, antibody testing, and FDA approved saliva tests, including the new BinaxNOW Rapid Antigen Test Cards, and other point-of-care testing.

The expanded COVID-19 coverage group now covers services related to COVID-19 treatment, including hospitalizations, emergency room visits, urgent care visits, telemedicine visits, and office visits. Per CMS guidance, covered treatment services include monoclonal antibody treatments and administration, FDA approved treatments for COVID-19 specific diagnoses and other clinical manifestations of COVID-19, as well as specialized equipment and therapies (including preventive therapies). The specific applicable treatment codes can be found in the MMIS. Refer to NH DHHS Health Alerts [#51: Evusheld COVID-19 Monoclonal Antibody Therapy](#); [#45 SARS-CoV-2 Monoclonal Antibody Therapy Updates](#); [#24 Bamlanivimab](#) and [#26 Regeneron's monoclonal antibodies casirivimab and imdevimab](#) for more detail on these therapies. Additional Information found here: <https://www.covid19.nh.gov/resources/general-provider-covid-19-resources-and-information>.

[Vaccine](#) administration for FDA-approved vaccines is also fully covered under the Medicaid COVID-19 Group. This includes the Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson) first,

second, third and booster vaccine doses. Please refer to the NH DHHS vaccine Health Alerts located at <https://www.covid19.nh.gov/resources/vaccine-information> for more information.

Over-the-counter at-home antigen COVID-19 tests are now covered for Medicaid beneficiaries through Medicaid-enrolled pharmacies. Each beneficiary is eligible to attain a maximum of eight at-home tests per month and there will be no out-of-pocket costs to members for the tests. Beneficiaries will bring their at-home antigen tests to the pharmacy counter to receive coverage.

### **Is a provider referral needed for the COVID-19 test under the Medicaid COVID-19 Group?**

A written provider referral is not needed for an individual to receive a COVID-19 test. As with any other type of lab test, a clinical provider order must be submitted to the testing laboratory for the lab to test the specimen for COVID-19.

This eligibility group is covered under Medicaid Fee-For-Service; there is no MCO involvement.

### **Can providers bill for the BinaxNOW Rapid Antigen tests?**

Providers cannot bill for the actual COVID-19 test if the BinaxNOW antigen test cards were provided free to the providers. However, providers can bill the appropriate Evaluation and Management (E&M) code for evaluation and management of an individual that may result in a test using a BinaxNOW test card and the appropriate specimen collection code. The typical specimen code would be G2023 as these tests are primarily being used in outpatient settings (as opposed to inpatient hospital settings and Long Term Care Facilities).

Note that providers must report test results from BinaxNOW Rapid tests and all other Point-of-Care testing to NH Division of Public Health. Coronavirus Disease 2019 (COVID-19) Outbreak Health Alert Messages # 23 and 22 provide testing and reporting guidance for point-of-care testing as community transmission is increasing. See: [HAN #23](#) and [HAN #22](#).

### **Is there a limit to the number of COVID-19 tests an individual may receive under the Medicaid COVID-19 Group?**

Our understanding at this time is that there is not a limit on the number of medically necessary tests an individual may have as long as the medical necessity is determined by an appropriate clinical provider. Tests that are not considered medically necessary and for the direct benefit of the patient are not covered under this Medicaid COVID-19 Group (or under Medicaid generally.) Please refer to the NH DHHS HANs [#19: COVID-19 Outbreak Update](#), [#23: Antigen Testing Updated Recommendations](#) regarding recommendations for testing, which includes persons with even mild symptoms of COVID-19 and asymptomatic patients, [HAN #22: Community Transmission of COVID-19 Increasing in NH; Instructions for Reporting COVID-19 Point-of-Care Test Results](#), and [HAN #52: Paxlovid and Molnupiravir Oral Antiviral Medications](#). Additional information on testing and reporting can be found at <https://www.covid19.nh.gov/resources/general-provider-covid-19-resources-and-information>.

### **How can an individual apply for the Medicaid COVID-19 Group?**

Individuals can fill out a simple, streamlined Medicaid application for this testing and treatment group directly filled out and processed electronically in NH EASY: <https://nheasy.nh.gov/#/> and clicking on the

“COVID-19” button in the middle of the page. Applications can also be e-mailed or mailed to individuals who choose not to apply online or are unable to apply electronically by calling (603) 271-7373 or by e-mailing the request for application at [BFA.800UI@dhhs.nh.gov](mailto:BFA.800UI@dhhs.nh.gov). Please be aware that this number is only for questions related to the Medicaid application for testing and treatment coverage; it is NOT for questions about test scheduling or for test results.

### **When does coverage begin for testing, vaccine administration, and treatment services under the Medicaid COVID-19 group?**

Coverage for diagnosis and testing services is as of March 18, 2020. Eligibility begins:

- 3/18/2020 for applications submitted prior to 6/17/2020 or
- 90 days before the application date for applications submitted on or after 6/17/2020
- Coverage for vaccine administration and treatment services is retroactive to March 11, 2021

### **How does the Medicaid COVID-19 Group relate to the HRSA COVID-19 Claims Reimbursement Program?**

The COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing and Treatment of the Uninsured Program provides reimbursements on a rolling basis directly to eligible providers for claims that are attributed to the testing, vaccine administration, and treatment of COVID-19 for uninsured individuals.

Individuals enrolled in the Medicaid Testing Group are considered to have insurance coverage for COVID-19 testing, diagnostic services, vaccine administration, and treatment. HRSA, via its claims contractor, United Health Care (UHC), will perform third party clearances with states' MMIS to ensure coordination of benefits for Medicaid beneficiaries. Because entry of beneficiaries enrolled in the COVID-19 Eligibility group into the MMIS may be delayed in some states, UHC will perform third party clearances at the initial receipt of a claim from providers and conduct periodic retrospective reviews.

If a HRSA payment has been made for an individual that has insurance coverage, payment will be recouped from the provider and the provider will need to bill the appropriate insurance.

This includes Medicaid coverage for this new group.

### **Should providers encourage uninsured individuals to apply for the Medicaid COVID-19 Group?**

Yes. By directing uninsured individuals to apply for the COVID-19 testing, vaccine administration, and treatment benefit through NH EASY, individuals can learn about the more comprehensive Medicaid program they may be eligible for as well as other DHHS benefit programs. There is no risk to the provider in enrolling an individual in the Medicaid COVID-19 Group. If the individual is determined to not meet the eligibility criteria, the provider can still submit for reimbursement for the COVID test through the HRSA program. If an individual enrolls in the Medicaid COVID-19 Group after their provider already submitted the relevant claim and received reimbursement from the HRSA program; HRSA will recoup the payment for the test but the provider will be reimbursed through Medicaid.

**What are the COVID-19 testing, vaccine administration and treatment codes?**

The most current reimbursement codes for COVID-19 testing and diagnosis related services, vaccine administration, and treatment services can be found in the MMIS and are updated regularly as additional coding and reimbursement information becomes available. For reference, CMS codes for vaccines and antibody treatments are located <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-mono-clonal-antibodies>. This is for information only; New Hampshire Medicaid rates can be located on the MMIS website.

**Please note that this information will be updated as CMS issues further guidance. NH DHHS will provide additional guidance as available.**